Cargando…

Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database

OBJECTIVES: Subcutaneous tumour necrosis factor alpha TNFαinhibitors (SC-TNFis) such as golimumab (GLM), adalimumab (ADA), etanercept (ETA) and certolizumab pegol (CZP) have been used for many years for the treatment of inflammatory arthritis. Non-adherence to therapy is an important modifiable fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhoi, Peter, Bessette, Louis, Bell, Mary J, Tkaczyk, Cathy, Nantel, Francois, Maslova, Karina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623530/
https://www.ncbi.nlm.nih.gov/pubmed/28928177
http://dx.doi.org/10.1136/bmjopen-2017-015872
_version_ 1783268109370523648
author Bhoi, Peter
Bessette, Louis
Bell, Mary J
Tkaczyk, Cathy
Nantel, Francois
Maslova, Karina
author_facet Bhoi, Peter
Bessette, Louis
Bell, Mary J
Tkaczyk, Cathy
Nantel, Francois
Maslova, Karina
author_sort Bhoi, Peter
collection PubMed
description OBJECTIVES: Subcutaneous tumour necrosis factor alpha TNFαinhibitors (SC-TNFis) such as golimumab (GLM), adalimumab (ADA), etanercept (ETA) and certolizumab pegol (CZP) have been used for many years for the treatment of inflammatory arthritis. Non-adherence to therapy is an important modifiable factor that may compromise patient outcomes. The aim of this analysis was to compare adherence and dosing interval of SC-TNFis in the treatment of people with inflammatory arthritis. DESIGN: We used the IMS Brogan database combining both Canadian private and public drug plan databases of Ontario and Quebec. Target drugs included SC-TNFis for inflammatory arthritis. The index period was from 1 January 2010 to 30 June 2012 and patients were followed for 24 months through 30 June 2014. Inclusion criteria were adult patients newly prescribed a SC-TNFis with at least three prescriptions and retained on therapy at 24 months. Dosing regimens as per the product monographs were used to compare actual versus expected drug utilisation. The mean possession ratio was used as a marker for adherence. Patients who scored >80% were considered adherent. The average days between units was estimated by taking the total days on therapy and divided by the number of units the patient received. RESULTS: 4035 patients were included: 683 (16.9%), 1400 (34.7%), 1765 (43.7%) and 187 (4.6%) were treated with GLM, ADA, ETA and CZP, respectively. The proportion of adherent patients in the GLM cohort (n=595/683, 87%, p<0.0001) was greater compared with ADA (n=1044/1400, 75%), ETA (n=1285/1765, 73%) and CZP-treated patients (132/187, 71%). In addition, the number of patients receiving biological drug at a shorter dosing interval was similar between cohorts, and was 5%, 6%, 12% and 4% in GLM (≤26 days), ADA (≤12 days), ETA (≤6 days) and CZP-treated patients (≤12 days), respectively. CONCLUSIONS: In this real-life administrative database, GLM had better adherence compared with other SC-TNFis.
format Online
Article
Text
id pubmed-5623530
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-56235302017-10-10 Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database Bhoi, Peter Bessette, Louis Bell, Mary J Tkaczyk, Cathy Nantel, Francois Maslova, Karina BMJ Open Rheumatology OBJECTIVES: Subcutaneous tumour necrosis factor alpha TNFαinhibitors (SC-TNFis) such as golimumab (GLM), adalimumab (ADA), etanercept (ETA) and certolizumab pegol (CZP) have been used for many years for the treatment of inflammatory arthritis. Non-adherence to therapy is an important modifiable factor that may compromise patient outcomes. The aim of this analysis was to compare adherence and dosing interval of SC-TNFis in the treatment of people with inflammatory arthritis. DESIGN: We used the IMS Brogan database combining both Canadian private and public drug plan databases of Ontario and Quebec. Target drugs included SC-TNFis for inflammatory arthritis. The index period was from 1 January 2010 to 30 June 2012 and patients were followed for 24 months through 30 June 2014. Inclusion criteria were adult patients newly prescribed a SC-TNFis with at least three prescriptions and retained on therapy at 24 months. Dosing regimens as per the product monographs were used to compare actual versus expected drug utilisation. The mean possession ratio was used as a marker for adherence. Patients who scored >80% were considered adherent. The average days between units was estimated by taking the total days on therapy and divided by the number of units the patient received. RESULTS: 4035 patients were included: 683 (16.9%), 1400 (34.7%), 1765 (43.7%) and 187 (4.6%) were treated with GLM, ADA, ETA and CZP, respectively. The proportion of adherent patients in the GLM cohort (n=595/683, 87%, p<0.0001) was greater compared with ADA (n=1044/1400, 75%), ETA (n=1285/1765, 73%) and CZP-treated patients (132/187, 71%). In addition, the number of patients receiving biological drug at a shorter dosing interval was similar between cohorts, and was 5%, 6%, 12% and 4% in GLM (≤26 days), ADA (≤12 days), ETA (≤6 days) and CZP-treated patients (≤12 days), respectively. CONCLUSIONS: In this real-life administrative database, GLM had better adherence compared with other SC-TNFis. BMJ Publishing Group 2017-09-18 /pmc/articles/PMC5623530/ /pubmed/28928177 http://dx.doi.org/10.1136/bmjopen-2017-015872 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Rheumatology
Bhoi, Peter
Bessette, Louis
Bell, Mary J
Tkaczyk, Cathy
Nantel, Francois
Maslova, Karina
Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database
title Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database
title_full Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database
title_fullStr Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database
title_full_unstemmed Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database
title_short Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database
title_sort adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a canadian administrative database
topic Rheumatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623530/
https://www.ncbi.nlm.nih.gov/pubmed/28928177
http://dx.doi.org/10.1136/bmjopen-2017-015872
work_keys_str_mv AT bhoipeter adherenceanddosingintervalofsubcutaneousantitumournecrosisfactorbiologicsamongpatientswithinflammatoryarthritisanalysisfromacanadianadministrativedatabase
AT bessettelouis adherenceanddosingintervalofsubcutaneousantitumournecrosisfactorbiologicsamongpatientswithinflammatoryarthritisanalysisfromacanadianadministrativedatabase
AT bellmaryj adherenceanddosingintervalofsubcutaneousantitumournecrosisfactorbiologicsamongpatientswithinflammatoryarthritisanalysisfromacanadianadministrativedatabase
AT tkaczykcathy adherenceanddosingintervalofsubcutaneousantitumournecrosisfactorbiologicsamongpatientswithinflammatoryarthritisanalysisfromacanadianadministrativedatabase
AT nantelfrancois adherenceanddosingintervalofsubcutaneousantitumournecrosisfactorbiologicsamongpatientswithinflammatoryarthritisanalysisfromacanadianadministrativedatabase
AT maslovakarina adherenceanddosingintervalofsubcutaneousantitumournecrosisfactorbiologicsamongpatientswithinflammatoryarthritisanalysisfromacanadianadministrativedatabase